Member Posts > Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL): Transforming Myocarditis Care - CardiolRx™'s Role in Inflammation Reduction
✔ Myocarditis remains a major cause of heart transplants among young adults.
✔ Without targeted therapy, many patients suffer long-term complications.
✔ CardiolRx™ directly addresses the inflammatory process fueling myocarditis.
How CardiolRx™ Works
✅ Reduces inflammation markers like IL-1β and IL-6.
✅ Prevents fibrosis, a major cause of heart failure.
✅ Phase II ARCHER Trial currently evaluating its long-term benefits.
🔗 Stay informed about CardiolRx™'s potential breakthrough for myocarditis patients:

#MedicalInnovation #HeartHealth